sellModerate cluster of 510b5-1 plan
Bruce Booth sold $56M of KYMR
director at Kymera Therapeutics, Inc.. 513,245 shares at an average of $110.01, traded Jun 26, 2026, filed Jun 30, 2026.
Warning score
40Value
$56M
513,245 shares
Holdings after
466,077
-18% from before
From 52-week low
+187%
low $37.68, close $108.12
From 52-week high
-7%
high $116.46, as of Jun 26, 2026
Score components
- +15RoleDirector
- +25Trade size$56.5M at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
KYMROct 12, 2026 · close 112.08
Since filing Jun 30, 2026: -2.3%SPY +4.5% · excess -6.7%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-26-000018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -28,296 | $107.57 | $3.0M | 2,834,055 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -231,007 | $108.14 | $25M | 2,603,048 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -32,624 | $109.79 | $3.6M | 2,570,424 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -11,277 | $110.49 | $1.2M | 2,559,147 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,366 | $111.51 | $1.2M | 2,548,781 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -555 | $112.49 | $62k | 2,548,226 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,913 | $113.97 | $1.7M | 2,533,313 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -27,951 | $114.94 | $3.2M | 2,505,362 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,821 | $115.69 | $789k | 2,498,541 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -12,181 | $117.09 | $1.4M | 2,486,360 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -22,046 | $117.85 | $2.6M | 2,464,314 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -12,390 | $118.66 | $1.5M | 2,451,924 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,958 | $107.57 | $426k | 525,760 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -32,402 | $108.14 | $3.5M | 493,358 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -4,562 | $109.79 | $501k | 488,796 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,579 | $110.49 | $174k | 487,217 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,442 | $111.51 | $161k | 485,775 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -78 | $112.49 | $8,774 | 485,697 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,083 | $113.97 | $237k | 483,614 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,896 | $114.94 | $448k | 479,718 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -952 | $115.69 | $110k | 478,766 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,701 | $117.09 | $199k | 477,065 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,069 | $117.85 | $362k | 473,996 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,729 | $118.66 | $205k | 472,267 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,471 | $105.78 | $579k | 2,446,453 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,613 | $106.63 | $1.6M | 2,431,840 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -19,093 | $107.76 | $2.1M | 2,412,747 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -848 | $105.78 | $90k | 471,419 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,318 | $106.63 | $247k | 469,101 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,024 | $107.76 | $326k | 466,077 | Jun 30, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $44M 398,765 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.